National Pension Service Has $334.14 Million Stock Position in Amgen Inc. $AMGN

National Pension Service boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,184,060 shares of the medical research company’s stock after purchasing an additional 37,747 shares during the quarter. National Pension Service owned 0.22% of Amgen worth $334,142,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Twin City Private Wealth LLC increased its holdings in shares of Amgen by 2.3% during the third quarter. Twin City Private Wealth LLC now owns 4,283 shares of the medical research company’s stock worth $1,209,000 after purchasing an additional 95 shares during the period. Winnow Wealth LLC acquired a new stake in Amgen during the third quarter worth approximately $47,000. AlphaQuest LLC bought a new position in Amgen during the 3rd quarter worth $937,000. Trifecta Capital Advisors LLC raised its holdings in Amgen by 3.6% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 14,919 shares of the medical research company’s stock valued at $4,210,000 after acquiring an additional 520 shares in the last quarter. Finally, Cahill Financial Advisors Inc. bought a new stake in shares of Amgen during the 3rd quarter valued at $299,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 10,908 shares of company stock worth $3,674,966 over the last ninety days. 0.76% of the stock is owned by insiders.

Amgen Stock Down 0.3%

Shares of NASDAQ AMGN opened at $341.88 on Friday. The company has a 50 day simple moving average of $332.60 and a 200 day simple moving average of $309.22. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $353.25. The firm has a market cap of $184.10 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 3.02 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s payout ratio is currently 73.57%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of analyst reports. Argus boosted their price target on Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. Royal Bank Of Canada increased their price target on shares of Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. BMO Capital Markets lifted their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Oppenheimer set a $400.00 price target on Amgen and gave the company an “outperform” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $342.45.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.